News
07.10.2020
Revisiting the influence of ICER in the US

ICER’s Health Technology Assessments review process is an assessment undertaken by one of three ap...

Read more
Articles
17.09.2020
The value of a Global Value Dossier

GVD is a core document, which may be considered the “heart” of the pharmaceutical product’s pa...

Read more
Articles
13.08.2020
What is Health Technology Assessment (HTA)

A multidisciplinary process that uses explicit methods to determine the value of a health technology...

Read more
Articles
29.07.2020
Real world data included in NICE

How has the data available within NCRAS been utilized within the CDF overseen by NICE, in partnershi...

Read more
Articles
28.07.2020
SMC restarts medicines appraisals process

The SMC has recently announced that it is beginning to restart its medicines appraisal process in a ...

Read more
Articles
24.06.2020
Changes to NICE single technology appraisals

NICE has decided to adapt the technical engagement step in a hope to improve stakeholder inclusion, ...

Read more
Articles
23.06.2020
COVID-19 impact on pricing and market access

Without a doubt, the impact of COVID-19 will influence all sectors, including the future of market a...

Read more
Articles
12.05.2020
Price and market access price affected by COVID

We received fabulous feedback, with responses from at least 15 industry executives across global pha...

Read more
Articles
05.05.2020
Remote delivery of market access training

Whilst many businesses are currently working remotely, up-skilling your workforce through interactiv...

Read more
Articles
30.04.2020
EU P&MA implications for developments

CAR T-cell therapies and speculation in the pricing and market access implications for the lymphoma ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.